Hernday Natasha

SEC source: 0001193125-26-303723 · ownership.xml · derivative · entry 7

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,881 shares

Expires 2034-05-15

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F6 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303723 · ownership.xml · derivative · entry 6

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,967 shares

Expires 2033-05-17

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F6 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303723 · ownership.xml · derivative · entry 5

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,996 shares

Expires 2032-05-18

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F6 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303723 · ownership.xml · derivative · entry 4

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,101 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F6 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303723 · ownership.xml · derivative · entry 3

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,251 shares

Expires 2030-06-30

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F6 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303723 · ownership.xml · nonDerivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · shares: Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · price: Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.

SEC source: 0001193125-26-303723 · ownership.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F2 · shares: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration").

F3 · shares: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F2 · price: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration").

F3 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.

SEC source: 0001780547-26-000004 · form4-06122026_080607.xml · derivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,500

Underlying: Common Stock · 15,500 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001780547-26-000004 · form4-06122026_080607.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,481

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001214659-26-006747 · marketforms-73267.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,592

F1 · shares: Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued service to the Company through such vesting date.

SEC source: 0001415889-25-017313 · form4-06132025_070608.xml · derivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,667

Underlying: Common Stock · 11,667 shares

Expires 2035-06-10

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-25-017313 · form4-06132025_070608.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,731

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001214659-25-008320 · marketforms-69669.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,006

F1 · shares: Consists of 5,971 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest on the first anniversary of the grant date, subject to the reporting person's continued service to the Company through such vesting date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · derivative · entry 4

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-07-18

F4 · derivative.exercise_date: The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · derivative · entry 3

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,700

Underlying: Common Stock · 16,700 shares

Expires 2034-07-18

F3 · derivative.exercise_date: The shares subject to the option will vest in thirty-six equal monthly installments over three years, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · nonDerivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

F2 · shares: Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-019903 · form4-07232024_120716.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in thirty-six equal monthly installments over a three year period, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-020056 · form4a-07242024_080702.xml · derivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,111

Underlying: Common Stock · 4,111 shares

Expires 2034-07-18

F2 · derivative.exercise_date: The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-020056 · form4a-07242024_080702.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,231

F1 · shares: Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.

SEC source: 0001626199-24-000100 · wk-form4_1716250414.xml · derivative · entry 5

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires 2034-01-01

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F7 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001626199-24-000100 · wk-form4_1716250414.xml · derivative · entry 4

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2033-01-02

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F2 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

SEC source: 0001626199-24-000100 · wk-form4_1716250414.xml · derivative · entry 3

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2032-01-02

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F2 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

SEC source: 0001626199-24-000100 · wk-form4_1716250414.xml · derivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,650 shares

Expires 2031-01-03

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F2 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

SEC source: 0001626199-24-000100 · wk-form4_1716250414.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2030-12-09

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F2 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

SEC source: 0001214659-24-009521 · marketforms-65902.xml · derivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,881

Underlying: Common Stock · 4,881 shares

Expires 2034-05-15

F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 15, 2024), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the reporting person's continued service to the Company through each vesting date.

SEC source: 0001214659-24-009521 · marketforms-65902.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,035

F1 · shares: Consists of 3,035 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest on the first anniversary of the grant date, subject to the reporting person's continued service to the Company through such vesting date.

SEC source: 0001626199-24-000013 · wk-form4_1704413182.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2034-01-01

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001214659-23-007559 · marketforms-61568.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,967

Underlying: Common Shares · 10,967 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 17, 2023), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option.

SEC source: 0001626199-23-000018 · wf-form4_167296307107599.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-01-02

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001214659-22-007244 · marketforms-56240.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,996

Underlying: Common Shares · 8,996 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 18, 2022), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option.

SEC source: 0001626199-22-000008 · wf-form4_164133502903188.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-01-02

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 3, 2022 and 1/12th of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001214659-21-005809 · marketforms-52855.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,101

Underlying: Common Shares · 5,101 shares

Expires 2031-05-19

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 19, 2021), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option.

SEC source: 0001626199-21-000023 · wf-form4_160989189280940.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Common Stock · 7,650 shares

Expires 2031-01-03

F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 4, 2021 and 1/12th of the shares subject to the option shall vest monthly thereafter.

SEC source: 0001214659-20-010508 · marketforms-50651.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

F1 · security: Ms. Hernday purchased 4,000 shares of the Issuer's 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the "Series A Preferred Stock"), in the Issuer's public offering at the public offering price of $25.00 per share. The terms of the Series A Preferred Stock are set forth in the Certificate of Designation of the 8.625% Series A Cumulative Perpetual Preferred Stock of the Issuer. Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the Issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.

SEC source: 0000899243-20-033579 · doc4.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-12-09

F1 · derivative.exercise_date: 1/36th of the shares subject to the option become vested and exercisable on 1/10/2021 and 1/36th of the shares subject to the option shall vest monthly thereafter.

SEC source: 0000882104-20-000135 · wf-form4_159826350941222.xml · derivative · entry 2

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,671

Underlying: Common stock · 118,671 shares

Expires 2030-08-19

F2 · derivative.exercise_date: The stock options will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date.

SEC source: 0000882104-20-000135 · wf-form4_159826350941222.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,826

F1 · shares: The restricted stock will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date.

SEC source: 0001214659-20-006110 · marketforms-49167.xml · derivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,251

Underlying: Common Shares · 13,251 shares

Expires 2030-06-30

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over three years from the date of grant (June 30, 2020).

SEC source: 0000882104-19-000074 · wf-form4_156142690185407.xml · nonDerivative · entry 1

Hernday Natasha · CIK 0001780547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders.